Ophélie Dufrançais

Ophélie Dufrançais

Auto-generated profile, based on publicly available information

Ophélie Dufrançais

Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) 1 , Toulouse

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2025 in Journal of Cell Biology
Verified
Journal Article
Open access
ODOphélie Dufrançais
Ophélie Dufrançais
MPMarianna Plozza
Marianna Plozza
MJMarie Juzans
Marie Juzans
AMArnaud Métais
Arnaud Métais
Sarah C. MonardSarah C. Monard
Sarah C. Monard
Christel VerolletChristel Verollet
Christel Verollet
Cell–cell fusion is an evolutionarily conserved process that is essential for many functions, including the formation of bone-resorbing multinucleated osteoclasts. Osteoclast multinucleation involves dynamic interactions between the actin cytoskeleton and the plasma membrane that are still poorly characterized. We found that moesin, a cytoskeletal linker protein member of the Ezrin, radixin, and moesin (ERM) protein family, plays a critical role in both osteoclast fusion and function. Moesin inhibition favors osteoclast multinucleation as well as HIV-1- and inflammation-induced cell fusion. Accordingly, moesin depletion decreases membrane-to-cortex attachment and enhances the formation of tunneling nanotubes, F-actin–based intercellular bridges triggering cell–cell fusion. In addition, moesin regulates the formation of the sealing zone, a key structure determining osteoclast bone resorption area, and thus controls bone degradation via a β3-integrin/RhoA/SLK pathway. Finally, moesin-deficient mice have reduced bone density and increased osteoclast abundance and activity. These findings provide a better understanding of cell–cell fusion and osteoclast biology, opening new opportunities to specifically target osteoclasts in bone disease therapy.